KYOTO, JAPAN -- (February 7, 2019) Exact Imaging (www.exactimaging.com), the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, and its ExactVu micro-ultrasound system will be featured prominently at the 11^th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer in Kyoto, Japan from February 9 – 11th, 2019. There will a main talk on the Applications for Focal Therapy using 29 MHz Micro-Ultrasound (Dr. Sangeet Ghai)andtwo oral poster presentations on “A Multi-Institutional Randomized Controlled Trial Comparing Novel First-Generation High-Resolution Micro-Ultrasound with Conventional Frequency Ultrasound for Transrectal Prostate Biopsy” (Ghai et al.)and “A Prospective Validation of the Diagnostic Accuracy of PRI-MUS for Prostate Cancer Risk Identification” (Luger at al.). In addition, 11 posters citing the ExactVu micro-ultrasound will be presented during the conference. Exact Imaging will also be exhibiting the ExactVu platform, along with the FusionVu application during the commercial exhibition. The conference and exhibit will be held at the Kyoto Hotel Okura in Kyoto, Japan.

“We are proud that ExactVu micro-ultrasound continues to build strong adoption worldwide and that our clinical evidence base continues to amass from leading centers of excellence through to smaller community urology practices,” says Randy AuCoin, Exact Imaging’s President and CEO. “The ExactVu micro-ultrasound system provides the highest real-time resolution for targeted prostate biopsies and the results being generated across our extensive network of customers shows the utility of the system for improving practitioners’ abilities to visualize and guide their targeted biopsies”.

The following posters citing the clinical utility of the ExactVu micro-ultrasound system will be presented at the conference:

• A Multi-Institutional Randomized Controlled Trial Comparing Novel First-Generation High-Resolution Micro-Ultrasound with Conventional Frequency Ultrasound for Transrectal Prostate Biopsy
  


• Added Value of mpMRI and High-Resolution 29 MHz Micro-Ultrasound Targeting During Prostate Biopsy on Suspicion of Prostate Cancer
  


• Initial Results Comparing High-Resolution Micro-Ultrasound with Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection


• Can High-Resolution Micro-Ultrasound Detect Extra-Prostatic Extension: A New Sonographic Feature


• Initial Results Comparing High-Resolution Micro-Ultrasound with mpMRI for Prostate Cancer Detection


• Improving Standard Transrectal Prostate Biopsy Results Using High Resolution Micro-Ultrasound Real-Time Targeting for Suspicious Areas


• A Prospective Validation of the Diagnostic Accuracy of PRI-MUSTM for Prostate Cancer Risk Identification


• Initial Clinical Experience with 29 MHz Micro-Ultrasound for Real-Time Targeted Prostate Biopsies


• Risk Stratification for Equivocal PI-RADS™ 3 Results: Can Micro-Ultrasound Help Determine Which Men to Biopsy?


• Comparison of Micro-Ultrasound and Multiparametric MRI Imaging for Prostate Cancer: An International Meta-Analysis


• Accuracy of Micro-Ultrasound for Identification of Prostate Cancer: A Comparative Study with Whole Mount Pathology

About Exact Imaging

Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist (i.e., prior negative biopsies), the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates MRI fusion-based targeting. The ExactVu micro-ultrasound system including the FusionVu application have received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).